Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actuate 1801: Elraglusib (9-ING-41) with gemcitabine + nab-paclitaxel in metastatic pancreatic cancer
2024-518409-16-00Phase 2Completed
- Sponsor
- Actuate Therapeutics
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of elraglusib in pancreatic cancer (PC) (3 arms), sponsored by Actuate Therapeutics. Primary endpoint: 1-year overall survival rate. Started Oct 2024; status: completed.
02
Drugs
elraglusib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2024-518409-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518409-16-00.